AstraZeneca (NASDAQ:AZN) announced Tuesday at the J.P. Morgan Healthcare Conference that it has acquired Boston-based Modella AI, marking the first time a major pharmaceutical company has fully absorbed a specialized artificial intelligence firm.
The deal aims to accelerate drug discovery by bringing "foundation models" and generative AI agents directly into AstraZeneca's oncology research and development ecosystem.
While financial terms were not disclosed, the acquisition is an aggressive expansion of a "test drive" partnership the two companies launched in July 2025.
By moving Modella’s team and technology in-house, AstraZeneca intends to automate the most complex parts of clinical development—specifically quantitative pathology and biomarker discovery.
Modella AI’s technology specializes in analyzing biopsies and clinical data simultaneously to identify "hidden" proteins and patterns that human researchers might miss.
AstraZeneca CFO Aradhana Sarin noted that these tools would allow the company to develop "highly targeted therapeutics" by more accurately selecting the right patients for clinical trials, potentially cutting years off development timelines and reducing the massive costs associated with failed trials.
The acquisition was one of several high-profile AI alliances unveiled in San Francisco this week, as the industry pivots toward what many are calling the "AI-in-the-loop" paradigm.
AstraZeneca’s decision to buy Modella outright, rather than simply licensing its software, reflects a growing trend of "talent and data grabs" by pharmaceutical giants looking to build proprietary supercomputing advantages.